Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp (original) (raw)
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29 PubMed Google Scholar
Gatenby RA (2009) A change of strategy in the war on cancer. Nature 459:508–509 CASPubMed Google Scholar
Harguindey S, Orive G, Luis Pedraz J, Paradiso A, Reshkin SJ (2005) The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin–one single nature. Biochim Biophys Acta 1756:1–24 CASPubMed Google Scholar
Undevia SD, Gomez-Abuin G, Ratain MJ (2005) Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5:447–458 CASPubMed Google Scholar
Paxton JW (1986) The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, _N_-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits. J Pharm Pharmacol 38:837–840 CASPubMed Google Scholar
McLeod HL, Evans WE (1999) Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 5:2669–2671 CASPubMed Google Scholar
DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557–2567 CASPubMed Google Scholar
Fujiwara Y (1999) Current status of oral anticancer drugs in Japan. J Clin Oncol 17:3362–3365 CASPubMed Google Scholar
Sharma S (2001) Patient selection for oral chemotherapy. Oncology (Williston Park) 15(1 Suppl 2):33–35 CAS Google Scholar
Thörn M, Finnström N, Lundgren S, Rane A, Lööf L (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60:54–60 PubMed CentralPubMed Google Scholar
Wacher VJ, Salphati L, Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89–102 CASPubMed Google Scholar
Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF et al (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–2035 CASPubMed CentralPubMed Google Scholar
Burger H, Nooter K (2004) Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 3:1502–1505 CASPubMed Google Scholar
Dietrich CG, Geier A, Oude Elferink RPJ (2003) ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52:1788–1795 CASPubMed CentralPubMed Google Scholar
Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174 CASPubMed Google Scholar
Ling J, Fettner S, Lum BL, Riek M, Rakhit A (2008) Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 19:209–216 CASPubMed Google Scholar
Jain RK, Brar SS, Lesko LJ (2010) Food and oral antineoplastics: more than meets the eye. Clin Cancer Res 16:4305–4307 PubMed Google Scholar
Kang SP, Ratain MJ (2010) Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res 16:4446–4451 CASPubMed CentralPubMed Google Scholar
Herben VM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batchelor D, Doyle E (1999) Oral topotecan: bioavailablity and effect of food co-administration. Br J Cancer 80:1380–1386 PubMed CentralPubMed Google Scholar
Kivistö KT, Niemi M, Fromm MF (2004) Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 18:621–626 PubMed Google Scholar
He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252–259 CASPubMed Google Scholar
Fujita K (2004) Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20:195–217 CASPubMed Google Scholar
Singh BN, Malhotra BK (2004) Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 43:1127–1156 CASPubMed Google Scholar
Ruggiero A, Cefalo MG, Coccia P, Mastrangelo S, Maurizi P, Riccardi R (2012) The role of diet on the clinical pharmacology of oral antineoplastic agents. Eur J Clin Pharmacol 68:115–122 CASPubMed Google Scholar
Wilson K (1984) Sex-related differences in drug disposition in man. Clin Pharmacokinet 9:189–202 CASPubMed Google Scholar
Pleym H, Spigset O, Kharasch ED, Dale O (2003) Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand 47:241–259 CASPubMed Google Scholar
Alfarouk KO, Shayoub MEAA, Muddathir AK, Elhassan GO, Bashir AHHH (2011) Evolution of tumor metabolism might reflect carcinogenesis as a reverse evolution process (dismantling of multicellularity). Cancers (Basel) 3:3002–3017 CAS Google Scholar
Soldin OP, Chung SH, Mattison DR (2011) Sex differences in drug disposition. J Biomed Biotechnol 2011:187103 PubMed CentralPubMed Google Scholar
Beierle I, Meibohm B, Derendorf H (1999) Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37:529–547 CASPubMed Google Scholar
Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71–87 CASPubMed Google Scholar
Theologides A (1977) Nutritional management of the patient with advanced cancer. Postgrad Med 61:97–101 CASPubMed Google Scholar
Fearon KC (1992) The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 51:251–265 CASPubMed Google Scholar
Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345–1350 CASPubMed Google Scholar
Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20:219–222 CASPubMed Google Scholar
Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 38:1677–1684 CASPubMed Google Scholar
Tillement JP, Zini R, d’ Athis P, Vassent G (1974) Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters. Eur J Clin Pharmacol 7:307–313 CASPubMed Google Scholar
Ruiz-Cabello F, Erill S (1984) Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 36:691–695 CASPubMed Google Scholar
Goldwasser P, Feldman J (1997) Association of serum albumin and mortality risk. J Clin Epidemiol 50:693–703 CASPubMed Google Scholar
Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA (2003) Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J Parenter Enteral Nutr 27:10–15 CASPubMed Google Scholar
Grimm G, Haslacher H, Kampitsch T, Endler G, Marsik C, Schickbauer T et al (2009) Sex differences in the association between albumin and all-cause and vascular mortality. Eur J Clin Invest 39:860–865 CASPubMed Google Scholar
Liu B, Earl HM, Poole CJ, Dunn J, Kerr DJ (1995) Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 36:506–512 CASPubMed Google Scholar
Liliemark E, Söderhäll S, Sirzea F, Gruber A, Osby E, Björkholm M et al (1996) Higher in vivo protein binding of etoposide in children compared with adult cancer patients. Cancer Lett 106:97–100 CASPubMed Google Scholar
Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S et al (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625–632 CASPubMed Google Scholar
Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD (2006) Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24:291–297 PubMed Google Scholar
Wu J, Lorusso PM, Matherly LH, Li J (2012) Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097. Clin Cancer Res 18:2066–2079 CASPubMed Google Scholar
Levi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593–628 CASPubMed Google Scholar
Sukumaran S, Almon RR, DuBois DC, Jusko WJ (2010) Circadian rhythms in gene expression: relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev 62:904–917 CASPubMed CentralPubMed Google Scholar
Takahashi JS, Hong H-K, Ko CH, McDearmon EL (2008) The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 9:764–775 CASPubMed CentralPubMed Google Scholar
Straub RH, Cutolo M (2007) Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 56:399–408 PubMed Google Scholar
Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:377–421 PubMed Google Scholar
Prémaud A, Rousseau A, Gicquel M, Ragot S, Manceau J, Laurentie M et al (2002) An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. Toxicol Appl Pharmacol 183:189–197 PubMed Google Scholar
Baraldo M (2008) The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 4:175–192 CASPubMed Google Scholar
Erkekoglu P, Baydar T (2012) Chronopharmacokinetics of drugs in toxicological aspects: a short review for pharmacy practitioners. J Res Pharm Pract 1:3–9 CASPubMed CentralPubMed Google Scholar
Touitou Y, Touitou C, Bogdan A, Reinberg A, Auzeby A, Beck H et al (1986) Differences between young and elderly subjects in seasonal and circadian variations of total plasma proteins and blood volume as reflected by hemoglobin, hematocrit, and erythrocyte counts. Clin Chem 32:801–804 CASPubMed Google Scholar
Bruguerolle B, Arnaud C, Levi F, Focan C, Touitou Y, Bouvenot G (1989) Physiopathological alterations of alpha 1 acid glycoprotein temporal variations: implications for chronopharmacology. Prog Clin Biol Res 300:199–214 CASPubMed Google Scholar
Hecquet B, Meynadier J, Bonneterre J, Adenis L, Demaille A (1985) Time dependency in plasmatic protein binding of cisplatin. Cancer Treat Rep 69:79–83 CASPubMed Google Scholar
Hecquet B, Sucche M (1986) Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve. J Pharmacokinet Biopharm 14:79–93 CASPubMed Google Scholar
Lévi F (2006) Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control 17:611–621 PubMed Google Scholar
Guengerich FP (2007) Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 21:163–168 CASPubMed Google Scholar
Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70–83 CASPubMed Google Scholar
Jancova P, Anzenbacher P, Anzenbacherova E (2010) Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:103–116 CASPubMed Google Scholar
Gonzalez FJ (2006) Goodman and Gilman’s Pharmacological Basis of Therapeutics. In: Brunton LLLL, Lazo JS (eds) The McGraw-Hill Companies, Inc, New York, pp 71–92
Rooseboom M, Commandeur JNM, Vermeulen NPE (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53–102 CASPubMed Google Scholar
Akhdar H, Legendre C, Caroline Aninat FM (2012) Topics on drug metabolism. In: Paxton J (ed) INTECH, pp 137–170
McFadyen MCE, Melvin WT, Murray GI (2004) Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3:363–371 CASPubMed Google Scholar
Rodriguez-Antona C, Ingelman-Sundberg M (2006) Cytochrome P450 pharmacogenetics and cancer. Oncogene 25:1679–1691 CASPubMed Google Scholar
Lin JH, Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535–567 CASPubMed Google Scholar
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526 CASPubMed Google Scholar
Plant N (2007) The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 1770:478–488 CASPubMed Google Scholar
Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445–600 CASPubMed Google Scholar
Xu C, Li CY-T, Kong A-NT (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249–268 CASPubMed Google Scholar
Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J et al (1990) Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem 265:4296–4301 CASPubMed Google Scholar
Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R (1997) Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79:2336–2344 CASPubMed Google Scholar
Harkey MA, Czerwinski M, Slattery J, Kiem H-P (2005) Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest 23:19–25 CASPubMed Google Scholar
Kauvar LM, Morgan AS, Sanderson PE, Henner WD (1998) Glutathione based approaches to improving cancer treatment. Chem Biol Interact 111–112:225–238 PubMed Google Scholar
Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ et al (2005) Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33:1083–1096 CASPubMed Google Scholar
Kodym R, Calkins P, Story M (1999) The cloning and characterization of a new stress response protein. A mammalian member of a family of theta class glutathione s-transferase-like proteins. J Biol Chem 274:5131–5137 CASPubMed Google Scholar
Cumming RC, Lightfoot J, Beard K, Youssoufian H, O’Brien PJ, Buchwald M (2001) Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 7:814–820 CASPubMed Google Scholar
Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22:7369–7375 CASPubMed Google Scholar
Gunnarsdottir S, Elfarra AA (1999) Glutathione-dependent metabolism of cis-3-(9H-purin-6-ylthio)acrylic acid to yield the chemotherapeutic drug 6-mercaptopurine: evidence for two distinct mechanisms in rats. J Pharmacol Exp Ther 290:950–957 CASPubMed Google Scholar
Tew KD (2005) TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 14:1047–1054 CASPubMed Google Scholar
Nelson HH, Wiencke JK, Christiani DC, Cheng TJ, Zuo ZF, Schwartz BS et al (1995) Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 16:1243–1245 CASPubMed Google Scholar
Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM (1996) Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71:123–126 CASPubMed Google Scholar
LA Magno V, Talbot J, Talbot T, Borges Santos AM, Souza RP, Marin LJ (2009) Glutathione s-transferase variants in a brazilian population. Pharmacology 83:231–236 CASPubMed Google Scholar
Ying X-J, Dong P, Shen B, Xu C-Z, Xu H-M, Zhao S-W (2012) Glutathione S-transferase M1 gene polymorphism and laryngeal cancer risk: a meta-analysis. PLoS One 7:e42826 CASPubMed CentralPubMed Google Scholar
Liu J, Chen H, Miller DS, Saavedra JE, Keefer LK, Johnson DR et al (2001) Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60:302–309 CASPubMed Google Scholar
Lévi F, Altinok A, Clairambault J, Goldbeter A (2008) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos Trans A Math Phys Eng Sci 366:3575–3598 PubMed Google Scholar
Zeng Z-L, Sun J, Guo L, Li S, Wu M, Qiu F et al (2005) Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. Chronobiol Int 22:741–754 CASPubMed Google Scholar
Smaaland R, Sothern RB, Laerum OD, Abrahamsen JF (2002) Rhythms in human bone marrow and blood cells. Chronobiol Int 19:101–127 CASPubMed Google Scholar
Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144–160 CASPubMed Google Scholar
Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, Muraro GB (1988) Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 18:849–856 CASPubMed Google Scholar
Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273–297 CASPubMed Google Scholar
Ritter JK (2007) Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 3:93–107 CASPubMed Google Scholar
Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607 CASPubMed Google Scholar
Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA et al (2009) Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104:130–137 PubMed Google Scholar
Kusuhara H, Sugiyama Y (2002) Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release 78:43–54 CASPubMed Google Scholar
Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD et al (2001) ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 108:303–309 CASPubMed CentralPubMed Google Scholar
Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC et al (2002) Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 110:671–680 CASPubMed CentralPubMed Google Scholar
Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Elferink RPJO, Lagas JS et al (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319–327 CASPubMed Google Scholar
Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R et al (2004) Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J Biol Chem 279:2790–2799 CASPubMed Google Scholar
Vree TB, Van Ewijk-Beneken Kolmer EW, Wuis EW, Hekster YA, Broekman MM (1993) Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. Pharm World Sci 15:197–202 CASPubMed Google Scholar
Morris ME, Lee H-J, Predko LM (2003) Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol Rev 55:229–240 CASPubMed Google Scholar
Johnson JA (2000) Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 38:53–60 CASPubMed Google Scholar
Loadman PM, Bibby MC (1994) Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet 26:486–500 CASPubMed Google Scholar
Siemann DW (2006) Tumor vasculature : a target for anticancer therapies. In: Vascular-targeted therapies in oncology. John Wiley & Sons, Ltd, Chichester, pp 1–8
Alfarouk KO, Ibrahim ME, Gatenby RA, Brown JS (2013) Riparian ecosystems in human cancers. Evol Appl 6:46–53 PubMed CentralPubMed Google Scholar
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674 CASPubMed Google Scholar
Ma J, Waxman DJ (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7:3670–3684 CASPubMed CentralPubMed Google Scholar
Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171–1175 CASPubMed Google Scholar
Lloyd MC, Alfarouk KO, Verduzco D, Bui MM, Gillies RJ, Ibrahim ME et al (2014) Vascular measurements correlate with estrogen receptor status. BMC Cancer 14:279 PubMed CentralPubMed Google Scholar
Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF et al (2009) Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 69:2260–2268 CASPubMed CentralPubMed Google Scholar
Lippens RJ (1984) Methotrexate. I. Pharmacology and pharmacokinetics. Am J Pediatr Hematol Oncol 6:379–395 CASPubMed Google Scholar
Singh MS, Francis PA, Michael M (2011) Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 20:111–118 PubMed Google Scholar
Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764 CASPubMed Google Scholar
Caraci F, Crupi R, Drago F, Spina E (2011) Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 12:570–577 CASPubMed Google Scholar
Yap KYL, Tay WL, Chui WK, Chan A (2011) Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care (Engl) 20:6–32 Google Scholar
Yamazaki M, Suzuki H, Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497–513 CASPubMed Google Scholar
König J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377–394 PubMed Google Scholar
Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y (2005) Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314:876–882 CASPubMed Google Scholar
Kamisako T, Ogawa H (2004) Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat. J Gastroenterol Hepatol 19:879–883 CASPubMed Google Scholar
Raghunand N, Martínez-Zaguilán R, Wright SH, Gillies RJ (1999) pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 57:1047–1058 CASPubMed Google Scholar
Mahoney BP, Raghunand N, Baggett B, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207–1218 CASPubMed Google Scholar
Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627 CASPubMed Google Scholar
Stewart DJ (2007) Saturable passive resistance in chemotherapy of epithelial maligancies. In: Parsons RA (ed) Progress in cancer drug resistance research. Nova Science, New York, pp 29–41
De Visser KE, Jonkers J (2009) Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr Pharm Des 15:1844–1853 PubMed Google Scholar
Barlow M, Hall BG (2002) Phylogenetic analysis shows that the OXA β-lactamase genes have been on plasmids for millions of years. J Mol Evol 55:314–321 CASPubMed Google Scholar
Hall BG, Barlow M (2004) Evolution of the serine beta-lactamases: past, present and future. Drug Resist Updat 7:111–123 CASPubMed Google Scholar
Baltz RH (2008) Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 557–563
D’Costa VM, King CE, Kalan L, Morar M, Sung WWL, Schwarz C et al (2011) Antibiotic resistance is ancient. Nature 477:457–461 PubMed Google Scholar
Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, Johnston MD et al (2012) Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One 7:e34953 CASPubMed CentralPubMed Google Scholar
Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I (1987) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262:505–508 CASPubMed Google Scholar
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A et al (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124 CASPubMed Google Scholar
Zhou S-F (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38:802–832 CASPubMed Google Scholar
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738 CASPubMed CentralPubMed Google Scholar
Schinkel A (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179–194 CASPubMed Google Scholar
Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH et al (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458–3464 CASPubMed Google Scholar
Schuetz EG, Schinkel AH, Relling MV, Schuetz JD (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001–4005 CASPubMed CentralPubMed Google Scholar
Munteanu E, Verdier M, Grandjean-Forestier F, Stenger C, Jayat-Vignoles C, Huet S et al (2006) Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem Pharmacol 71:1162–1174 CASPubMed Google Scholar
Bendayan R, Ronaldson PT, Gingras D, Bendayan M (2006) In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 54:1159–1167 CASPubMed CentralPubMed Google Scholar
Solazzo M, Fantappiè O, D’Amico M, Sassoli C, Tani A, Cipriani G et al (2009) Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res 69:7235–7242 CASPubMed Google Scholar
Shen Y, Chu Y, Yang Y, Wang Z (2012) Mitochondrial localization of P-glycoprotein in the human breast cancer cell line MCF-7/ADM and its functional characterization. Oncol Rep 27:1535–1540 CASPubMed Google Scholar
Solazzo M, Fantappiè O, Lasagna N, Sassoli C, Nosi D, Mazzanti R (2006) P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res 312:4070–4078 CASPubMed Google Scholar
Babakhanian K, Bendayan M, Bendayan R (2007) Localization of P-glycoprotein at the nuclear envelope of rat brain cells. Biochem Biophys Res Commun 361:301–306 CASPubMed Google Scholar
Wei LY, Roepe PD (1994) Low external pH and osmotic shock increase the expression of human MDR protein. Biochemistry 33:7229–7238 CASPubMed Google Scholar
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654 CASPubMed Google Scholar
Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7:1798–1804 CASPubMed Google Scholar
Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG et al (2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem 286:6979–6988 CASPubMed CentralPubMed Google Scholar
Sauna ZE, Ambudkar SV (2007) About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6:13–23 CASPubMed Google Scholar
Keppler D, Leier I, Jedlitschky G, König J (1998) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem Biol Interact 111–112:153–161 PubMed Google Scholar
Keppler D (1999) Export pumps for glutathione S-conjugates. Free Radic Biol Med 27:985–991 CASPubMed Google Scholar
Coley HM (2008) Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34:378–390 CASPubMed Google Scholar
Cole SPC, Deeley RG (2006) Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 27:438–446 CASPubMed Google Scholar
Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931–959 CASPubMed Google Scholar
Sauna ZE, Smith MM, Müller M, Kerr KM, Ambudkar SV (2001) The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33:481–491 CASPubMed Google Scholar
Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27–42 CASPubMed Google Scholar
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939 CASPubMed Google Scholar
Cress RH, Deaver NL (1964) Methotrexate in the management of severe psoriasis and arthritis: report of a case. South Med J 57:1088–1090 CASPubMed Google Scholar
Dale J, Alcorn N, Capell H, Madhok R (2007) Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol 3:450–458 quiz, following 478 CASPubMed Google Scholar
Curt GA, Carney DN, Cowan KH, Jolivet J, Bailey BD, Drake JC et al (1983) Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 308:199–202 CASPubMed Google Scholar
Schimke RT (1984) Gene amplification, drug resistance, and cancer. Cancer Res 44:1735–1742 CASPubMed Google Scholar
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792 CASPubMed Google Scholar
Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338 CASPubMed Google Scholar
Watson RG, Muhale F, Thorne LB, Yu J, O’Neil BH, Hoskins JM et al (2010) Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. Eur J Cancer 46:3358–3364 CASPubMed CentralPubMed Google Scholar
Wang T-L, Diaz LA, Romans K, Bardelli A, Saha S, Galizia G et al (2004) Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 101:3089–3094 CASPubMed CentralPubMed Google Scholar
Reshkin SJ, Cardone RA, Harguindey S (2013) Na+-H+ exchanger, pH regulation and cancer. Recent Pat Anticancer Drug Discov 8:85–99 CASPubMed Google Scholar
Neri D, Supuran CT (2011) Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 10:767–777 CASPubMed Google Scholar
Huber V, De Milito A, Harguindey S, Reshkin SJ, Wahl ML, Rauch C et al (2010) Proton dynamics in cancer. J Transl Med 8:57 PubMed CentralPubMed Google Scholar
Alfarouk KO, Muddathir AK, Shayoub MEA (2011) Tumor acidity as evolutionary spite. Cancers (Basel) 3:408–414 Google Scholar
Hao N-B, Lü M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M (2012) Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012:948098 PubMed CentralPubMed Google Scholar
Correia AL, Bissell MJ (2012) The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 15:39–49 CASPubMed CentralPubMed Google Scholar
Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM (2002) MRI of the tumor microenvironment. J Magn Reson Imaging 16:430–450 PubMed Google Scholar
Raghunand N, Gillies RJ (2000) pH and drug resistance in tumors. Drug Resist Updat 3:39–47 CASPubMed Google Scholar
Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ (2011) Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 8:2032–2038 CASPubMed CentralPubMed Google Scholar
Raghunand N, Mahoney BP, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol 66:1219–1229 CASPubMed Google Scholar
Gong Y, Duvvuri M, Krise JP (2003) Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem 278:50234–50239 CASPubMed Google Scholar
Parkins CS, Chadwick JA, Chaplin DJ (1996) Inhibition of intracellular pH control and relationship to cytotoxicity of chlorambucil and vinblastine. Br J Cancer Suppl 27:S75–S77 CASPubMed CentralPubMed Google Scholar
Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HHB et al (2014) Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience 1:777–802 PubMed CentralPubMed Google Scholar
Harguindey S, Pedraz JL, García Cañero R, Pérez de Diego J, Cragoe EJ (1995) Hydrogen ion-dependent oncogenesis and parallel new avenues to cancer prevention and treatment using a H(+)-mediated unifying approach: pH-related and pH-unrelated mechanisms. Crit Rev Oncog 6:1–33 CASPubMed Google Scholar
Harguindey S, Arranz JL, Polo Orozco JD, Rauch C, Fais S, Cardone RA et al (2013) Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs—an integral molecular/biochemical/metabolic/clinical approach after 100 years of cancer research. J Transl Med 11:282 PubMed CentralPubMed Google Scholar
Van Meir E (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential to solid tumours. Neurosurgery 39:878–879 PubMed Google Scholar
Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB et al (2007) Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 97:646–653 CASPubMed CentralPubMed Google Scholar
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW et al (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88–91 CASPubMed Google Scholar
Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M (1998) A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 2:259–265 CASPubMed Google Scholar
Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. Oncologist 9(Suppl 5):10–17 CASPubMed Google Scholar
Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM (1991) Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 64:809–814 CASPubMed CentralPubMed Google Scholar
Suzuki Y, Tanaka K, Neghishi D, Shimizu M, Murayama N, Hashimoto T et al (2008) Increased distribution of carboplatin, an anti-cancer agent, to rat brains with the aid of hyperbaric oxygenation. Xenobiotica 38:1471–1475 CASPubMed Google Scholar
Lara PC, Lloret M, Clavo B, Apolinario RM, Henríquez-Hernández LA, Bordón E et al (2009) Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat Oncol 4:29 PubMed CentralPubMed Google Scholar
Kim JW, Ho WJ, Wu BM (2011) The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. Anticancer Res 31:3237–3245 CASPubMed Google Scholar
Cosse J-P, Michiels C (2008) Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 8:790–797 CASPubMed Google Scholar
Zhu H, Chen XP, Luo SF, Guan J, Zhang WG, Zhang BX (2005) Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 24:565–574 CASPubMed Google Scholar
Legendre C, Hori T, Loyer P, Aninat C, Ishida S, Glaise D et al (2009) Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur J Cancer 45:2882–2892 CASPubMed Google Scholar
Sullivan R, Paré GC, Frederiksen LJ, Semenza GL, Graham CH (2008) Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7:1961–1973 CASPubMed Google Scholar
Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF (2005) The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11(24 Pt 1):8782–8788 CASPubMed Google Scholar
Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592 CASPubMed Google Scholar
Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV (2012) Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci USA 109:13314–13318 CASPubMed CentralPubMed Google Scholar
Weinhouse S (1956) On respiratory impairment in cancer cells. Science 124:267–269 CASPubMed Google Scholar
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899 CASPubMed Google Scholar
Williams B, Howard RL (1994) Glucose-induced changes in Na+/H+ antiport activity and gene expression in cultured vascular smooth muscle cells. Role of protein kinase C. J Clin Invest 93:2623–2631 CASPubMed CentralPubMed Google Scholar
Fu Y, Lee AS (2006) Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 5:741–744 CASPubMed Google Scholar
Lyon RC, Cohen JS, Faustino PJ, Megnin F, Myers CE (1988) Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res 48:870–877 CASPubMed Google Scholar
Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P et al (2007) Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59:495–505 CASPubMed Google Scholar
Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A et al (2012) Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4:124ra27 PubMed CentralPubMed Google Scholar
Komurov K, Tseng J-T, Muller M, Seviour EG, Moss TJ, Yang L et al (2012) The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 8:596 PubMed CentralPubMed Google Scholar
Sevick EM, Jain RK (1989) Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 49:3506–3512 CASPubMed Google Scholar
Weiss L, Tveit E, Hultborn R (1985) Vascular resistance characteristics of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors and normal tissues as studied in vitro. Cancer Res 45:2478–2480 CASPubMed Google Scholar
Tveit E, Weiss L, Lundstam S, Hultborn R (1987) Perfusion characteristics and norepinephrine reactivity of human renal carcinoma. Cancer Res 47:4709–4713 CASPubMed Google Scholar
Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454 PubMed Google Scholar
Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB et al (2003) Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 17:1756–1758 CASPubMed Google Scholar
Késmárky G, Kenyeres P, Rábai M, Tóth K (2008) Plasma viscosity: a forgotten variable. Clin Hemorheol Microcirc 39:243–246 PubMed Google Scholar
Kwon O, Krishnamoorthy M, Cho YI, Sankovic JM, Banerjee RK (2008) Effect of blood viscosity on oxygen transport in residual stenosed artery following angioplasty. J Biomech Eng 130:011003 PubMed Google Scholar
Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573 CASPubMed Google Scholar
Aoudjit F, Vuori K (2012) Integrin Signaling in Cancer Cell Survival and Chemoresistance. Chemother Res Pract 1–16
Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60:2497–2503 CASPubMed Google Scholar
Rintoul RC, Sethi T (2001) The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2:437–442 CASPubMed Google Scholar
Rintoul RC, Sethi T (2002) Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 102:417–424 CAS Google Scholar
Naci D, El Azreq M-A, Chetoui N, Lauden L, Sigaux F, Charron D et al (2012) α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem 287:17065–17076 CASPubMed CentralPubMed Google Scholar
Haslam IS, Jones K, Coleman T, Simmons NL (2008) Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem Pharmacol 76:850–861 CASPubMed Google Scholar
Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311–318 CASPubMed Google Scholar
Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M (2001) Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. Drug Metab Dispos 29:145–151 CASPubMed Google Scholar
Aquilante CL, Letrent SP, Pollack GM, Brouwer KL (2000) Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 66:47–51 Google Scholar
El Hafny B, Chappey O, Piciotti M, Debray M, Boval B, Roux F (1997) Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line. Neurosci Lett 236:107–111 PubMed Google Scholar
Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ et al (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604 PubMed Google Scholar
Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K (1999) Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol 58:1801–1806 CASPubMed Google Scholar
Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Méria P et al (2006) Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 70:1019–1025 CASPubMed Google Scholar
Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K (1999) Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull 22:1355–1359 CASPubMed Google Scholar
Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW et al (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41–49 CASPubMed Google Scholar
Callaghan R, Riordan JR (1993) Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 268:16059–16064 CASPubMed Google Scholar
Callaghan R, Higgins CF (1995) Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 71:294–299 CASPubMed CentralPubMed Google Scholar
Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YKK et al (2006) Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol 76:85–92 CASPubMed Google Scholar
Jovelet C, Bénard J, Forestier F, Farinotti R, Bidart JM, Gil S (2012) Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. Eur J Pharm Sci 46:484–491 CASPubMed Google Scholar
Xu H-B, Li L, Fu J, Mao X-P, Xu L-Z (2012) Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene. Pharmacology 89:303–312 CASPubMed Google Scholar